Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
Authors
Keywords
-
Journal
Biomed Research International
Volume 2018, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2018-02-26
DOI
10.1155/2018/1812535
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy
- (2017) Neha Kamran et al. MOLECULAR THERAPY
- Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
- (2017) Veronica Huber et al. SEMINARS IN CANCER BIOLOGY
- Mechanism of immune evasion in breast cancer
- (2017) Mozhi Wang et al. OncoTargets and Therapy
- Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma
- (2017) Wen-Guang He et al. Oncotarget
- Transforming growth factor-β: A therapeutic target for cancer
- (2017) Sulsal Haque et al. Human Vaccines & Immunotherapeutics
- The MYCN Protein in Health and Disease
- (2017) María Victoria Ruiz-Pérez et al. Genes
- MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma
- (2017) Elisa Brandetti et al. OncoImmunology
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
- (2017) Irene Scarfò et al. Journal for ImmunoTherapy of Cancer
- Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
- (2017) Matthias Van Woensel et al. Scientific Reports
- Driving an improved CAR for cancer immunotherapy
- (2016) Xiaopei Huang et al. JOURNAL OF CLINICAL INVESTIGATION
- Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development
- (2016) Okito Hashimoto et al. JOURNAL OF PATHOLOGY
- CAFs and TAMs: maestros of the tumour microenvironment
- (2016) Yoshihiro Komohara et al. JOURNAL OF PATHOLOGY
- Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
- (2016) Takahiro Aoki et al. PEDIATRIC BLOOD & CANCER
- Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion
- (2016) Zijun Zhen et al. Oncotarget
- Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients
- (2016) Mark A. Applebaum et al. Oncotarget
- Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients
- (2016) Fabio Morandi et al. Journal of Immunology Research
- Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
- (2016) Yelei Guo et al. Journal of Immunology Research
- CD4+CD25hiCD127− Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma
- (2016) Fabio Morandi et al. OncoImmunology
- Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma
- (2016) Gabriele Büchel et al. OncoImmunology
- Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2
- (2016) Jan Müller et al. PLoS One
- Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
- (2015) Muhammad Zaeem Noman et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- New horizons in tumor microenvironment biology: challenges and opportunities
- (2015) Fei Chen et al. BMC Medicine
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity
- (2015) F. Mussai et al. CANCER RESEARCH
- Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signaling pathway
- (2015) THITINEE VANICHAPOL et al. Molecular Medicine Reports
- Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer
- (2015) Simone Punt et al. PLoS One
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome
- (2015) Fabio Morandi et al. Journal of Immunology Research
- Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma
- (2015) Marco Mina et al. OncoImmunology
- PD-L1 and CD8+PD1+lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy
- (2015) Ferdousi Chowdhury et al. OncoImmunology
- Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity
- (2014) Valentina Rigo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
- (2014) Ann M Leen et al. MOLECULAR THERAPY
- Circulating T-Regulatory Cells in Neuroblastoma: A Pilot Prospective Study
- (2014) TVSVGK Tilak et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment
- (2014) G Bianchi et al. Cell Death & Disease
- Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
- (2013) Matthew D. Vesely et al. Annals of the New York Academy of Sciences
- Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice
- (2013) D. Chinnasamy et al. CANCER RESEARCH
- Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma
- (2013) Lena-Maria Carlson et al. CARCINOGENESIS
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway
- (2013) Chao-Ying Liu et al. LABORATORY INVESTIGATION
- Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
- (2013) Sunitha Kakarla et al. MOLECULAR THERAPY
- Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
- (2013) L.-C. S. Wang et al. Cancer Immunology Research
- NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses
- (2013) Alessandra Zingoni et al. Frontiers in Immunology
- Neuroblastoma-related inflammation
- (2013) Lena-Maria Carlson et al. OncoImmunology
- Immunosuppressive Microenvironment in Neuroblastoma
- (2013) Vito Pistoia et al. Frontiers in Oncology
- A Galectin-3-Dependent Pathway Upregulates Interleukin-6 in the Microenvironment of Human Neuroblastoma
- (2012) A. M. Silverman et al. CANCER RESEARCH
- IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity
- (2012) Daofeng Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
- (2012) Shahab Asgharzadeh et al. JOURNAL OF CLINICAL ONCOLOGY
- Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma
- (2011) W. Jing et al. BLOOD
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing
- (2011) Lei Bao et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Behavior of seeds and soil in the mechanism of metastasis: A deeper understanding
- (2011) Lucy Mathot et al. CANCER SCIENCE
- Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments
- (2011) Rocio Soldati et al. INTERNATIONAL JOURNAL OF CANCER
- The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
- (2011) Elisabetta Fratta et al. Molecular Oncology
- Immunology and immunotherapy of neuroblastoma
- (2011) Robert C. Seeger SEMINARS IN CANCER BIOLOGY
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor
- (2008) Aaron E. Foster et al. JOURNAL OF IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started